格隆汇5月7日丨药师帮(09885.HK)宣布，其拟根据股东于2024年5月23日举行的公司股东周年大会上以 股东决议案通过授予董事会回购公司股份(「股份」)的一般授权("2024年股份回购授权")行使有关权 力。根据2024年股份回购授权，董事会可行使公司权力，以回购不超过于2024年股东周年大会当日已发 行股份总数10%的股份，即最多64,088,640股股份。 为使公司可于适当时灵活回购股份，于2025年5月21日举行的应届股东周年大会上将提呈普通决议案， 批准授予董事股份回购授权，以于联交所回购不超过公司于应届股东周年大会当日已发行股份总数(不 包括任何库存股份)10%的股份。 董事会决定，视乎市况而定，公司拟动用最多1亿港元，以根据2024年股份回购授权于2025年股东周年 大会前不时于公开市场回购股份。 董事会进一步决定，待股东批准2025年股份回购授权后，视乎市况而定，公司拟于2025年股东周年大会 日期至2025年10月31日期间，根据2025年股份回购授权动用可用的回购预算于公开市场回购股份。 董事会认为，公司目前的股价低于其真正价值，未能充分反映其业务前景。董事会认为，建议股份回购 计划显 ...

Group 1 - The company, Yaoshi Bang (9885.HK), has initiated a share buyback program, repurchasing 300,000 shares for approximately HKD 2.104 million at an average price of HKD 7.0147 per share, with plans to utilize up to HKD 1 billion for further buybacks by October 31, 2025, indicating positive expectations for its performance and market future [1][2] - The company's financial performance has shown significant improvement, with a reported revenue of HKD 17.904 billion for 2024, representing a year-on-year growth of 5.5%, and a net profit of HKD 157 million, up 20.1%, marking its first annual profit [1] - The company has demonstrated strong cash flow management, with inventory turnover days at only 31 days and a cash cycle of -28.9 days, highlighting its effective inventory and cash management practices [1] Group 2 - The company is characterized as a "cigar butt stock" due to its stable operations and abundant cash flow, which are currently undervalued in the market, attracting attention from public funds [2] - Analysts suggest that the potential for short-term valuation recovery exists, as the stock price may revert to its intrinsic value with improved market sentiment or industry conditions, while quality companies can achieve long-term value enhancement through operational improvements [2] - With ongoing domestic policy support for optimizing grassroots medical resource allocation, companies like Yaoshi Bang, which have a digitalization advantage, are expected to enter a rapid development phase, creating opportunities for medium to long-term investments [2]

药师帮公告，公司董事会拟根据2024年股东周年大会授予的股份回购授权，于2025年股东周年大会前不 时在公开市场回购股份，动用金额不超过1亿港元。首次回购已于2025年5月7日进行，回购30万股，总 金额约为210.44万港元，平均回购价为每股7.01港元。回购股份将适时注销。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 自願性公告 (1) 股份回購計劃 (2)股份回購 此公告乃藥師幫股份有限公司（「本公司」）自願向本公司股東（「股 東」）及本公司 潛 在 投 資 者 作 出。 根 據《聯 交 所 證 券 上 市 規 則》（「《上 市 規 則》」），每 股 股 份 的 實 際 回 購 價 不 得 超 出 緊接每次回購前五個交易日股份平均收市價5%。本 公 司 將 以 現 有 可 用 現 金 提 供 回 購 股 份 的 資 金，而 根 據 股 份 回 購 計 劃 回 購 的 任 何 股 份 將 適 時 註 銷。 董 事 會 認 為，本 公 司 目 前 的 股 價 低 於 其 真 正 價 值，未 能 充 分 反 映 其 業 務 前 景。 董 事 ...

Company Overview - Yaoshi Bang Co., Ltd. was established in 2015 and is the largest digital comprehensive service platform in China's outpatient pharmaceutical industry [3] - The company aims to empower participants in the outpatient pharmaceutical market through digitalization, including pharmaceutical companies, distributors, pharmacies, and grassroots medical institutions [3] - Yaoshi Bang's mission is to make quality medical products and services accessible at fair and transparent prices, enhancing the overall efficiency of the healthcare ecosystem [3] Financial Performance - As of December 31, 2024, Yaoshi Bang achieved total revenue of 17.904 billion yuan, representing a year-on-year growth of 5.49% [1] - The net profit attributable to shareholders was 30.013 million yuan, showing a significant year-on-year increase of 100.94% [1] - The gross profit margin stood at 10.13%, with a debt-to-asset ratio of 65.07% [1] Market Position and Valuation - Currently, there are no institutional investment ratings for Yaoshi Bang [2] - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.22 times, with a median of 4.58 times [2] - Yaoshi Bang's P/E ratio is significantly higher at 137.82 times, ranking 77th in the industry [2] - Comparatively, other companies in the sector have much lower P/E ratios, such as Qingyou Pharmaceutical at 0.72 times and Jinsui Biotechnology at 1.03 times [2] Business Scale and Reach - In 2023, Yaoshi Bang's total Gross Merchandise Volume (GMV) reached 46.9 billion yuan, covering 401,000 pharmacies and 246,000 grassroots medical institutions [3] - The company penetrates 98.6% of county-level areas and 88.4% of townships nationwide, with an average of 367,000 active buyers per month [3] - Yaoshi Bang has established the largest digital pharmaceutical trading and service network in the country [3]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部分內容所產生或因依賴該等內容而引致的任何損失承擔任何責 任。 YSB Inc. 藥師幫股份有限公司 （於 開 曼 群 島 註 冊 成 立 的 有 限 公 司） （股 份 代 號：9885） 股東週年大會通告 茲通告藥師幫股份有限公司（「本公司」）謹訂於2025年5月21日（星 期 三）上午十時 正假座中華人民共和國廣州市海珠區新港中路397號品牌街8號會議室舉行股 東 週 年 大 會，藉 以 處 理 下 列 事 項： – 1 – 1. 省覽本公司截至2024年12月31日止年度的經審計綜合財務報表及董事會報 告 以 及 審 計 師 報 告。 2. 就截至2024年12月31日止年度宣派末期股息每股人民幣0.075元。 3. 考慮並酌情批准下列決議案（各 項 均 作 為 獨 立 決 議 案）： (a) 重 選 陳 飛 先 生 為 執 行 董 事； (b) 重 選 孫 含 暉 先 生 為 獨 立 非 執 行 董 ...

此乃要件 請即處理 閣下如 對本通函任何方面或應採取的行動 有任何疑問，應諮詢股票經紀或其他註冊證券 交易商、銀行經理、律師、專業會計師或其他專業顧問。 閣下如已售出或轉讓 名下所有藥師幫股份有限公司股份，應立即將本通函連同隨附代表 委 任 表 格 送 交 買 家 或 承 讓 人 或 經 手 買 賣 或 轉 讓 的 銀 行、股 票 經 紀 或 其 他 代 理 商，以 便 轉 交買家或承讓人。 香港交易及結算所有限公司及香港聯合交易所有限公司對本通函的內容概不負責，對其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 通 函 全 部 或 任 何 部 分 內 容 所產生或因依賴該等內容而引致的任何損失承擔任何責任。 YSB Inc. 藥師幫股份有限公司 （於開曼群島註冊成立的有限公司） （股份代號：9885） 本通函所述日期及時間均指香港日期及時間。 2025年4月25日 | | | | 頁 次 | | --- | --- | --- | --- | | | | 釋 義 | 1 | | 董事會函件 | | | | | 1. | | 緒 言 | 3 | | 2. ...

| 公司簡介 | 01 | | --- | --- | | 首席執行官寄語 | 06 | | 關於本報告 | 08 | | ESG 管理 | 05 | | 企業管治 | 19 | | --- | --- | | 風險管理 | 21 | | 商業道德 | 25 | | 產品安全與品質 | 31 | | --- | --- | | 價格實惠穩供應 | 43 | | 好藥普及與推廣 | 47 | | 全方位服務支持 | 53 | | 應對氣候變化 | 77 | | --- | --- | | 綠色運營 | 84 | | 綠色價值鏈 | 91 | | 供應鏈管理 | 95 | | --- | --- | | 互相成就,共同成長 | 103 | | 投身社會公益 | 115 | | ESG關鍵績效指標披露 | | --- | | ESG報告守則內容索引 | | 意見反饋表 | 2024 年度環境、社會及管治報告 公司簡介 首席執行官寄語 關於本報告 ESG 管理 穩健治理高效運營 好醫好藥普惠可及 科技賦能創新引領 雙碳引航綠色發展 夥伴責任共同發展 附錄 公司簡介 關於藥師幫 藥師幫自 2015 年成立以來，已成為中 ...

Financial Performance - Revenue for the year ended December 31, 2024, was RMB 17,903,608, representing a 5.5% increase from RMB 16,972,276 in 2023[8] - Adjusted net profit for the year was RMB 156,734, a 20.1% increase compared to RMB 130,542 in 2023[8] - The gross profit for the year was RMB 1,813,451, reflecting a 4.2% increase from RMB 1,740,923 in 2023[8] - The company declared a full-year dividend of RMB 0.075 per share, marking a return to profitability[8] - The group achieved a profit of RMB 15.1 million for the year ending December 31, 2024, compared to a loss of RMB 3,206.5 million for the year ended December 31, 2023[66] - Adjusted net profit increased by 20.1% from RMB 130.5 million for the year ended December 31, 2023, to RMB 156.7 million for the year ending December 31, 2024[69] - Cash and cash equivalents increased by 39.6% from RMB 745.7 million as of December 31, 2023, to RMB 1,041.2 million as of December 31, 2024[73] - Net cash generated from operating activities was RMB 655.9 million for the year ending December 31, 2024, compared to RMB 451.2 million for the year ended December 31, 2023[74] Business Growth and Expansion - The number of non-pharmaceutical product SKUs on the platform increased by approximately 50% during the reporting period[12] - The platform successfully onboarded around 600 traditional Chinese medicine manufacturers, enhancing product quality control from the supply chain[12] - The cumulative registered buyers exceeded 827,000, including 491,000 pharmacies and 330,000 primary medical institutions, with average monthly active buyers growing by 18.0% year-over-year[25] - The average monthly paid buyers reached 401,000, reflecting a year-over-year increase of 17.2%, with a payment rate of 92.7%[25] - The platform attracted over 15,000 upstream sellers and over 820,000 downstream buyers by the end of 2024[28] - The company completed the acquisition of 100% equity in "Yikua Pharmaceutical" for approximately RMB 1.035 billion, enhancing its proprietary brand business[15] - The company covered 330,000 grassroots medical institutions, adding over 80,000 new users compared to the previous year, with registered buyers penetrating 98.9% of counties and 91.2% of townships nationwide[46] Operational Efficiency - The company's order fulfillment efficiency improved, with same-day delivery orders increasing from 58.6% to 68.9% year-over-year[14] - The average order processing time in warehouses was about 3 hours, with cross-province delivery taking approximately 38 hours to cities and 49 hours to towns[30] - The unit fulfillment cost for same-city delivery decreased by 12.87%, while the proportion of orders delivered within half a day increased from 58.6% in 2023 to 68.9% in 2024[30] - The return rate decreased from 0.5% in the previous year to 0.4% during the reporting period[31] - The smart supply chain management system enabled an average order processing time of about 3 hours, significantly faster than the industry average, with accounts payable turnover days at approximately 66.1 days[44] Digital Transformation and Technology - The company is focusing on digital transformation and enhancing SaaS solutions, integrating AI and big data to improve system efficiency and user satisfaction[18] - The introduction of the "Spectrum Cabin" smart healthcare solution aims to enhance primary healthcare service efficiency and quality[18] - The "Spectrum Cloud Diagnosis" SaaS service had over 660 paying users by December 31, 2024, improving operational efficiency for grassroots medical institutions[40] - The company plans to enhance collaboration with upstream pharmaceutical companies to build a tighter upstream ecosystem and expand its proprietary brand product lineup[52] - The company aims to optimize its supply chain management and improve operational efficiency through advanced AI capabilities and the integration of its SaaS product matrix[52] Corporate Governance and Social Responsibility - The company is committed to ESG practices, receiving multiple awards for its social responsibility efforts during the reporting period[19] - The company is committed to social responsibility, including employee welfare and environmental protection[123] - The company is focused on strengthening its management team with professionals from diverse backgrounds in finance, technology, and corporate governance[170] - The company is actively pursuing new strategies for market expansion and product development, leveraging the expertise of its newly appointed directors[176] - The company aims to enhance its corporate governance framework by integrating the insights of its independent directors into strategic decision-making[175] Shareholder Information and Incentive Plans - The board proposed a final dividend of RMB 0.075 per share, equivalent to HKD 0.081, subject to shareholder approval at the upcoming annual general meeting[113] - The company adopted two share incentive plans during the reporting period: the 2019 Share Incentive Plan and the 2023 Share Incentive Plan, with a total of 11,775,400 new shares to be issued under these plans, representing approximately 1.79% of the company's issued shares[187] - The 2019 Share Incentive Plan has an authorization limit of 47,772,984 shares, while the 2023 Share Incentive Plan has an authorization limit of 63,235,005 new shares, with an annual cap of 2% of the total issued shares post-listing[189] - The total number of unexercised options under the 2019 Share Incentive Plan is 34,831,068 shares, which is 4.49% of the company's issued shares[189] - The company aims to align the interests of participants with those of shareholders to promote business success through these incentive plans[185]

Core Viewpoint - The Chinese pharmaceutical B2B e-commerce market has experienced rapid growth from 2015 to 2019, with sales exceeding 100 billion yuan in 2019. However, sales declined in 2020 due to the pandemic, and in 2023, sales reached 125.3 billion yuan, a year-on-year decrease of 18.16%. Future growth is expected as policies improve and the outpatient market develops [1][18]. Industry Overview - Pharmaceutical e-commerce, defined as the online trading of medical products, can be categorized into B2B, B2C, and O2O models, each serving different market segments and enhancing efficiency in the pharmaceutical distribution industry [3][4]. - The B2B model primarily serves medical institutions and pharmacies, focusing on drug procurement and distribution, while the B2C model targets end consumers [4][9]. Industry Development History - The development of pharmaceutical B2B e-commerce in China has been influenced by government policies, transitioning from a phase of prohibition to encouragement. Significant milestones include the establishment of pilot programs in 2000 and the lifting of bans in 2005, leading to a market that reached over 100 billion yuan in 2019 [6][9]. Market Size and Growth - In 2023, the total sales of the pharmaceutical distribution market reached 29.304 billion yuan, with a year-on-year growth of 7.5%. B2B sales accounted for over 70% of this market, indicating a strong demand for B2B services [14][15]. - The B2B e-commerce segment specifically generated 125.3 billion yuan in sales in 2023, representing 50.3% of the total pharmaceutical e-commerce sales [15][18]. Order and User Engagement - The number of orders in the pharmaceutical B2B e-commerce sector reached 81.68 million in 2023, a year-on-year increase of 13.49%, with a conversion rate of 97.3%. Active users on B2B platforms grew by 30.77% to 1.36 million [20][21]. Sales Structure - The sales structure of B2B e-commerce is predominantly focused on Western medicine, which accounts for 71.7% of sales, followed by traditional Chinese medicine at 21.9%. There is potential for growth in other categories as the market expands [21][24]. Key Companies - Major players in the pharmaceutical B2B e-commerce market include Jiuzhoutong, Yaoshibang, and others, which have established strong service and logistics capabilities, leading to significant customer retention [24][26][28]. Future Trends - The industry is expected to see a trend towards personalized and vertical development, with smaller companies focusing on niche markets. Additionally, B2B platforms will likely expand their service offerings to include diverse solutions for both upstream and downstream partners in the supply chain [30][31].